Nanomaterials: leading immunogenic cell death-based cancer therapies

作者：Changyu Ma, Zhe Cheng, Haotian Tan, Yihan Wang, Shuzhan Sun, Mingxiao Zhang, Jianfeng Wang · 发表于：Frontiers in Immunology · 年份：2024 · DOI：10.3389/fimmu.2024.1447817 · 被引用次数：29 · 研究领域：Nanoplatforms for cancer theranostics、Phagocytosis and Immune Regulation、Nanoparticle-Based Drug Delivery

The field of oncology has transformed in recent years, with treatments shifting from traditional surgical resection and radiation therapy to more diverse and customized approaches, one of which is immunotherapy. ICD (immunogenic cell death) belongs to a class of regulatory cell death modalities that reactivate the immune response by facilitating the interaction between apoptotic cells and immune cells and releasing specific signaling molecules, and DAMPs (damage-associated molecular patterns). The inducers of ICD can elevate the expression of specific proteins to optimize the TME (tumor microenvironment). The use of nanotechnology has shown its unique potential. Nanomaterials, due to their tunability, targeting, and biocompatibility, have become powerful tools for drug delivery, immunomodulators, etc., and have shown significant efficacy in clinical trials. In particular, these nanomaterials can effectively activate the ICD, trigger a potent anti-tumor immune response, and maintain long-term tumor suppression. Different types of nanomaterials, such as biological cell membrane-modified nanoparticles, self-assembled nanostructures, metallic nanoparticles, mesoporous materials, and hydrogels, play their respective roles in ICD induction due to their unique structures and mechanisms of action. Therefore, this review will explore the latest advances in the application of these common nanomaterials in tumor ICD induction and discuss how they can provide new strategies and tools for...